Ibrahim (Abe) Gökçe Yayla, Ph.D., Chief Executive Officer

 

Inanç Ortaç, Ph.D., Chief Technology Officer

 

Sadik Esener, Ph.D., Chairman of the Scientific Advisory Board

 

Bradley Messmer, Ph.D., Vice President R&D

 

Ibrahim (Abe) Gökçe Yayla, Ph.D.
Chief Executive Officer

Started multiple technology companies with successful exits, including InnoComm Wireless ($130M sale to National Semiconductor, 2000). Abe has multiple years of engineering management experience. He worked or performed consulting services for many major semiconductor companies including Intel, Fairchild, National Semiconductor, Cypress Semiconductor, Conexant, AMCC, PCSI, Trident, ABB Hafo, Nanogen, Nanotronics and Opti. Dr. Yayla is the author of multiple papers, holds 6 issued U.S. Patents, and contributed to more than 20 designs that went to production. Dr.Yayla received a Ph.D degree from UC San Diego in Electrical Engineering and Applied Physics.

 

Inanç Ortaç, Ph.D.
Chief Technology Officer

Dr. Ortaç has invented and developed the SHELS technology during his doctoral studies at Moores Cancer Center, University of California, San Diego. He won the grand prize in the national Collegiate Inventors Competition in 2012 with the SHELS technology. The SHELS technology also won the first prize in UC San Diego Entrepreneur Challenge in 2013. Previously, Inanc placed second in the UC San Diego Entrepreneur Challenge with a business plan for a different invention, a medical device for rapid on-site detection of hospital-acquired infections. He co-founded DevaCell Inc. around the SHELS technology and currently serves as the company’s chief technology officer. Dr. Ortaç is the author of several papers and holds 5 issued and pending patents.

 

Sadik Esener, Ph.D.
Chairman of the Scientific Advisory Board

Professor of Photonics and Nanotechnology. After leading UCSD’s OptoElectronic Computing Group for more than a decade, Dr. Esener became the director and Principal Investigator of the NanoTumor Center for Cancer Nanotechnology of Excellence funded by NCI. He has authored more than 100 journal publications and 250 conference abstracts. Esener co-founded San Diego-based Nanogen, Optical Micro-Machines, Parallel Solutions, Genoptix, and Call/Recall and Ziva.

 

Bradley Messmer, Ph.D.
Vice President R&D

Brad received his Ph.D. in molecular biology from the Rockefeller University in 2000 and did postdoctoral training in the laboratory of Dr. Nicholas Chiorazzi at the Feinstein Institute for Medical Research in Manhasset, New York. He went on to join the faculty there before moving to the Moores UCSD Cancer Center in 2004. Dr. Messmer’s work has focused on the application of novel technologies to problems in cancer diagnosis, monitoring, and treatment. He has developed a novel DNA nanoparticle platform that can target cancer cells, improved methods for isothermal DNA amplification, and developed assays for therapeutic biologics that are used in clinical trials, patient monitoring, and counterfeit detection. These highly interdisciplinary projects blend biology, biochemistry, informatics, and engineering with translational medicine for real world solutions to critical problems. In 2012, Dr. Messmer co-founded Devacell Inc with the team led by Dr Sadik Esener, with whom he has collaborated extensively since joining UCSD. Dr Messmer is author on over 20 scientific papers, inventor on 5 pending or issued patents, been an invited speaker at national/international meetings, and is both a recipient of and a reviewer for the NCI’s Innovative Molecular Analysis Technologies grant program.